Screener
Amphastar Pharmaceuticals AMPH Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Debt issuance costs | — | (675) |
| Proceeds from borrowing under lines of credit | — | 5,771 |
| Repayments under lines of credit | (478) | — |
| Principal payments on long-term debt | (76) | (75) |
| Net cash used in financing activities | (73,742) | (44,705) |
| Effect of exchange rate changes on cash | (122) | 260 |
| Net increase in cash, cash equivalents, and restricted cash | 53,437 | 36,080 |
| Cash, cash equivalents, and restricted cash at beginning of period | 170,412 | 151,844 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's debt repayments?
- Amphastar Pharmaceuticals (AMPH) reported debt repayments of $47K in Q2 2026.
- How has Amphastar Pharmaceuticals's debt repayments changed year-over-year?
- Amphastar Pharmaceuticals's debt repayments increased by 27.0% year-over-year, from $37K to $47K.
- What is the long-term trend for Amphastar Pharmaceuticals's debt repayments?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's debt repayments has grown at a -72.1% compound annual growth rate (CAGR), from $36.74M to $223K.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Amphastar Pharmaceuticals's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude